Published in Oncoimmunology on June 04, 2015
STAT3 inhibition for cancer therapy: Cell-autonomous effects only? Oncoimmunology (2016) 0.78
Targeting STAT3 signaling reduces immunosuppressive myeloid cells in head and neck squamous cell carcinoma. Oncoimmunology (2016) 0.75
miRNA-320a inhibits tumor proliferation and invasion by targeting c-Myc in human hepatocellular carcinoma. Onco Targets Ther (2017) 0.75
Role of microRNAs in inflammation-associated liver cancer. Cancer Biol Med (2016) 0.75
Human microRNA expression in sporadic and FAP-associated desmoid tumors and correlation with beta-catenin mutations. Oncotarget (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Cancer genome landscapes. Science (2013) 25.33
Origins and Mechanisms of miRNAs and siRNAs. Cell (2009) 20.77
Stat3 as an oncogene. Cell (1999) 17.39
STATs and gene regulation. Science (1997) 16.55
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science (1994) 11.33
An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell (2009) 10.09
SMAD proteins control DROSHA-mediated microRNA maturation. Nature (2008) 9.67
Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. Science (2012) 5.50
Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood (2007) 5.14
NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61
Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell (2009) 4.56
Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell (2011) 4.54
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell (2011) 4.12
Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 3.71
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med (2008) 3.68
Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell (2011) 3.47
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology (2010) 3.37
Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res (2005) 3.10
Stat3 and Stat4: members of the family of signal transducers and activators of transcription. Proc Natl Acad Sci U S A (1994) 2.81
Genetic mechanisms of hepatocarcinogenesis. Oncogene (2002) 2.21
miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res (2011) 2.00
The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell (2011) 1.92
MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem (2011) 1.88
Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology (2010) 1.81
Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma. Cancer Cell (2013) 1.81
MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol (2011) 1.76
MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology (2013) 1.69
Hepatoprotection via the IL-6/Stat3 pathway. J Clin Invest (2003) 1.51
Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res (2006) 1.46
Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer (2012) 1.41
Signal transducers and activators of transcription-from cytokine signalling to cancer biology. Biochim Biophys Acta (2011) 1.01
Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ (2014) 1.00
Downregulation of miR-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration. PLoS One (2012) 0.98
Analysis options for high-throughput sequencing in miRNA expression profiling. BMC Res Notes (2014) 0.96
miRNomes of haematopoietic stem cells and dendritic cells identify miR-30b as a regulator of Notch1. Nat Commun (2013) 0.95
Granulocyte colony-stimulating factor activates a 72-kDa isoform of STAT3 in human neutrophils. J Leukoc Biol (1998) 0.92
STAT signaling in the pathogenesis and treatment of myeloid malignancies. JAKSTAT (2012) 0.92
Hepatoprotective versus oncogenic functions of STAT3 in liver tumorigenesis. Am J Pathol (2011) 0.91
Stat3 and G-CSF-induced myeloid differentiation. Leuk Lymphoma (1998) 0.91
Small GTPase RBJ mediates nuclear entrapment of MEK1/MEK2 in tumor progression. Cancer Cell (2014) 0.84
Etiology of hepatocellular carcinoma influences clinical and pathologic features but not patient survival. Am J Gastroenterol (2003) 0.80